Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Chief Business Officer | February 17, 2021 | February 19, 2021 |
| uniQure N.V.QURE · Entity 4162 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Syros Pharmaceuticals, Inc.
Report date February 17, 2021 · Filed February 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.41 · Expires 2031-02-16 | Direct | 94,000 |
Reported balance
After 2021-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-17 · Grant · Acquired 94,000 · Balance 94,000 F1: This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.
uniQure N.V.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 43,251 |
Ending reported balance
After 2026-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-10 · Grant · Acquired 7,550 · Balance 45,244 F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Row 2 · 2026-06-11 · Sale · Disposed 1,993 · Balance 43,251 F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.82 · Expires 2036-06-10 | Direct | 13,980 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 13,980 · Balance 13,980 F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 21:45 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,993 | $27.06 | $53,930.58 |
DisclosureSEC source: 0000904454-26-000346 · edgar.xml · nonDerivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,251 F2 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:45 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 13,980 | $0.00 Strike: $26.82 | $0.00 |
DisclosureSEC source: 0000904454-26-000346 · edgar.xml · derivative · entry 3 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,980 Underlying: Ordinary Shares · 13,980 shares Expires 2036-06-10 F4 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:45 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-26-000346 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,244 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:08 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,112 | $14.45 | $30,518.40 |
DisclosureSEC source: 0000904454-25-000340 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,694 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.40 to $14.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:37 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,630 | $0.00 Strike: $16.22 | $0.00 |
DisclosureSEC source: 0000904454-25-000307 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Ordinary Shares · 15,630 shares Expires 2035-06-11 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:37 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,970 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-25-000307 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,806 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:14 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,840 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000904454-24-000405 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,840 Underlying: Ordinary Shares · 15,840 shares Expires 2034-06-19 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:14 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-24-000405 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,836 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:40 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,231 | $5.12 | $11,422.72 |
DisclosureSEC source: 0000904454-24-000375 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,756 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.12 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:06 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,286 | $18.88 | $43,159.68 |
DisclosureSEC source: 0000904454-23-000386 · edgar.xml · nonDerivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,987 F3 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F3 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.86 to $18.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:06 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,060 | $0.00 Strike: $20.18 | $0.00 |
DisclosureSEC source: 0000904454-23-000386 · edgar.xml · derivative · entry 3 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,060 Underlying: Ordinary Shares · 17,060 shares Expires 2033-06-13 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:06 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000386 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,273 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:12 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 384 | $20.41 | $7,837.44 |
DisclosureSEC source: 0000899243-23-006578 · doc4.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,573 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:18 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,810 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000904454-22-000350 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Ordinary Shares · 17,810 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:18 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 9,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000350 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,957 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:39 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 602 | $16.70 | $10,053.40 |
DisclosureSEC source: 0000904454-22-000217 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,877 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.70 to $16.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:35 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 2,645 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0000904454-22-000195 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645 Underlying: Ordinary Shares · 2,645 shares Expires 2032-02-24 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:35 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 1,534 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000195 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,479 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:53 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 505 | $37.50 | $18,937.50 |
DisclosureSEC source: 0000904454-21-000286 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,945 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.76 to $37.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:06 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 4,107 | $0.00 Strike: $37.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000256 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Underlying: Ordinary Shares · 4,107 shares Expires 2031-02-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:06 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000256 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,450 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:16 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 94,000 | $0.00 Strike: $11.41 | $0.00 |
DisclosureSEC source: 0001209191-21-012345 · doc4.xml · derivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:59 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 3,620 | $0.00 Strike: $51.81 | $0.00 |
DisclosureSEC source: 0000904454-20-000265 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,620 Underlying: Ordinary Shares · 3,620 shares Expires 2030-02-27 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:59 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000265 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,068 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 16:07 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 94,000 | $0.00 Strike: $7.54 | $0.00 |
DisclosureSEC source: 0001209191-20-009600 · doc4.xml · derivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. Read SEC document |
| January 28, 2020 Filed Jan 31, 2020 01:57 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 803 | $62.20 | $49,946.60 |
DisclosureSEC source: 0000904454-20-000108 · edgar.xml · nonDerivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,005 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. Read SEC document |
| January 28, 2020 Filed Jan 31, 2020 01:57 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 4 | $60.94 | $243.76 |
DisclosureSEC source: 0000904454-20-000108 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,808 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 16:34 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 10,121 | $4.97 | $50,267.97 |
DisclosureSEC source: 0001209191-19-056026 · doc4.xml · nonDerivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.88 to $5.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 16:34 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 9,879 | $4.99 | $49,327.82 |
DisclosureSEC source: 0001209191-19-056026 · doc4.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,879 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.95 to $5.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 17:19 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $6.71 | $0.00 |
DisclosureSEC source: 0001209191-19-010291 · doc4.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-02-11 F2 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares underlying the award on February 29, 2020, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 17:19 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantCommon Stock | 87,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010291 · doc4.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,000 F1 · shares: The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 21:49 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,210 | $31.32 | $37,897.20 |
DisclosureSEC source: 0000904454-19-000118 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,812 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $31.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2019 Filed Jan 30, 2019 01:43 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 5,295 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0000904454-19-000113 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,295 Underlying: Ordinary Shares · 5,295 shares Expires 2029-01-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 25, 2019 Filed Jan 30, 2019 01:43 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000113 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,022 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 16:51 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 6,390 | $0.00 Strike: $19.39 | $0.00 |
DisclosureSEC source: 0000904454-18-000080 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,390 Underlying: Ordinary Shares · 6,390 shares Expires 2028-01-26 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 16:51 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000080 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,792 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| December 15, 2017 Filed Dec 15, 2017 16:02 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 15,000 | $9.08 | $136,260.00 |
DisclosureSEC source: 0001179110-17-015427 · edgar.xml · nonDerivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.95 to $9.2099, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 17:15 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001179110-17-014121 · edgar.xml · derivative · entry 2 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-11-12 F2 · derivative.exercise_date: This option vests upon the achievement of performance-based criteria, and in any event will vest in full on November 13, 2023. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 17:15 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001179110-17-014121 · edgar.xml · derivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-11-12 F1 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares underlying the award on November 13, 2018, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award until November 13, 2021, subject to Dr. Springhorn's continued service as an employee through each applicable vesting date. Read SEC document |
| September 20, 2017 Filed Sep 26, 2017 21:15 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001209191-17-054007 · doc4.xml · derivative · entry 1 Springhorn Jeremy P. · CIK 0001717852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2027-09-20 F1 · derivative.exercise_date: The first tranche of 25% vests on September 20, 2018, with the remainder vesting in tranches of 6.25% each quarter thereafter over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.